International linkage grants and international fellows announced
21 July, 2005 by Graeme O'NeillFederal science minister Dr Brendan Nelson announced today the government will provide AUD$2,972,440 to fund 42 new awards for Australian-based researchers to participate in joint research projects with their overseas peers in 18 different countries, under the Australian Research Council's Linkage International Scheme.
BresaGen nets $200,000 SA govt grant
20 July, 2005 by Helen SchullerBresaGen (ASX:BGN) has been awarded a Commercial Infrastructure Grant of AUD$200,000 from Bio Innovation SA, the South Australian government's biotechnology agency.
Chemeq subscribers agree to extend convertible bond completion date
20 July, 2005 by Ruth BeranFollowing a trading halt, Chemeq (ASX:CMQ) has updated the market on the allotment and issue of AUD$20 million additional convertible bonds to Japanese investment group Mizuho International and related entities of investment management group Stark Investments, due on July 15.
In brief: Chemeq, Acuron, Compumedics, Synchrotron
19 July, 2005 by Staff WritersChemeq (ASX:CMQ) is in a trading halt in the lead-up to an announcement concerning the underwriting of AUD$20 million convertible bonds to Mizuho International, Stark Trading and Shephard Investments International, to which it committed itself in April.
Locals win grants to study in US
19 July, 2005 by Helen SchullerFellowship grants of more than AUD$270,000 have been awarded to seven Australian scientists to pursue research and studies at American Institutions courtesy, of the American Australian Association.
Genesis Biomedical granted option to purchase NZ company
19 July, 2005 by Ruth BeranGenesis Biomedical (ASX:GBL) has been granted an option to purchase 100 per cent of the issued capital of privately owned New Zealand based Manawatu Biotech Investments (MBI).
Biosignal, US partner to work on biofilm apps
19 July, 2005 by Graeme O'NeillSydney anti-microbial developer Biosignal (ASX:BOS) has linked up with a major US-based technology evaluation corporation to assess the market potential of its furanone anti-biofilm technology.
Biomira exercises rights in Prima
18 July, 2005 by Ruth BeranCanadian-based cancer vaccine company Biomira has exercised its put option to take up equity in Prima Biomed (ASX:PRR) by swapping its 10 per cent equity in Prima's subsidiary company CancerVac for approximately 1.62 per cent equity in Prima.
FASTS critical of ARC board sacking
18 July, 2005 by Graeme O'NeillThe Federation of Australian Scientific and Technological Societies (FASTS) has criticised a decision by the Minister for Education, Science and Training, Dr Brendan Nelson, to dissolve the board of the Australian Research Council from early next year.
In Brief: Polartechnics, Medsaic, Epitan, Genesis Research and Development Corporation, PharmAust, Advanced Molecular Technologies
15 July, 2005 by Staff WritersPolartechnics has announced an increase in unaudited revenue results for the financial year ending June 2005 by 280 per cent to AUD$6 million, compared to $2.1 million for the previous financial year.
Former Amrad CEO takes top job at Cerylid
14 July, 2005 by Ruth BeranTwo months after his surprise resignation as CEO of Amrad (ASX:AML), Peter Smith has taken on a part-time role as CEO of Cerylid Biosciences, an unlisted company of which Amrad is the major shareholder.
In Brief: Medical Developments International, Ventracor, Anadis, Ozgen, GlaxoSmithKline
14 July, 2005 by Staff WritersChris Weaver has resigned as Medical Developments Internationa (ASX:MVP) managing director and CEO to take up an executive management position with a bank. Current CFO Jeremy Payling will act as interim CEO while the company searches for a new CEO.
Avexa CEO: how we landed Shire deal
13 July, 2005 by Ruth BeranWhen asked about Avexa's (ASX:AVX) successful in-licensing of HIV drug AVX754 from UK company Shire Pharmaceuticals, Avexa's CEO, Julian Chick, likes to use the following anonymous quote: "How did a little Australian company with no proven ability in-license a phase II drug from a specialty pharma?"
GE sale offers new hope to Iatia
12 July, 2005 by Helen SchullerPhase imaging enhancement specialist Iatia (ASX:IAT) is showing the early stages of a turnaround following the signing of two deals within the last month.
The Burrill view: Get ready for biotech's next phase
07 July, 2005 by Iain ScottSteven Burrill's 'state of the industry' address is the star turn at the annual BIO conference in the US. Iain Scott was in the audience for this year's words of wisdom.
